EMA recommends restricting use of Tecovirimat SIGA
The medicine was not effective for the treatment of mpox in randomised clinical trials
Publisher
EU
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
The medicine was not effective for the treatment of mpox in randomised clinical trials
Source route
Continue on ema.europa.eu
Leave the platform to read the original full article on the publisher site.
Source: EMA Human Medicines
Scope: Regulatory
Related coverage
More related coverage
New treatment for relapsed extensive-stage small cell lung cancer
Imdylltra addresses unmet need in people with poor prognosis and limited treatment options
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2026
Five new medicines recommended for approval; another 13 medicines recommended for extension of their...
公告115年度「國家藥物科技研究發展獎」自公告日起至115年6月30日止受理申請。
公告115年度「國家藥物科技研究發展獎」自公告日起至115年6月30日止受理申請。
OMNIPAQUE 300 mg, OMNIPAQUE 350 mg Iodo /ml SOLUCION INYECTABLE y VISIPAQUE 320 mg /ml SOLUCION INYECTABLE
Formato pdf Fecha de publicación: 26 de marzo de 2026 Nº alerta: R_16/2026 Fecha: 25 de marzo de 202...